CO5160289A1 - Composicion farmaceutica que inhibe o detiene el crecimiento de viruses, en animales, particularmente mamiferos util para tratar infecciones virales - Google Patents
Composicion farmaceutica que inhibe o detiene el crecimiento de viruses, en animales, particularmente mamiferos util para tratar infecciones viralesInfo
- Publication number
- CO5160289A1 CO5160289A1 CO00023485A CO00023485A CO5160289A1 CO 5160289 A1 CO5160289 A1 CO 5160289A1 CO 00023485 A CO00023485 A CO 00023485A CO 00023485 A CO00023485 A CO 00023485A CO 5160289 A1 CO5160289 A1 CO 5160289A1
- Authority
- CO
- Colombia
- Prior art keywords
- hydrogen
- useful
- group
- pharmaceutical composition
- viral infections
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Botany (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Abstract
La presente invención se relaciona con una composición farmacéutica que comprende una cantidad segura y eficaz de un éster de ácido carbámico que tiene la fórmula:<EMI FILE="00023485_1" ID="1" IMF=JPEG >en donde X independientemente es oxigeno o azufre, R se selecciona del grupo que consiste de hidrógeno y aIquilo que tiene de 1 a 4 átomos de carbono, R1 se selecciona del grupo que consiste de hidrógeno y alquilo que tiene de 1 a 4 átomos de carbono, en donde R2 independientemente se selecciona del grupo que consiste de hidrógeno y alquilo que tiene de 1 a 4 átomos de carbono, y en donde Y se selecciona del grupo que consiste de hidrógeno, cloro, fluoro, bromo, hidroxi, oxicloro y sulfhidrilo o sales de adición farmacéuticas o un derivado enlazado covalentemente, disociable de ésta en donde el éster de ácido carbámico antes mencionado es útil para tratar infecciones virales.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28189399A | 1999-03-31 | 1999-03-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5160289A1 true CO5160289A1 (es) | 2002-05-30 |
Family
ID=23079212
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO00023485A CO5160289A1 (es) | 1999-03-31 | 2000-03-31 | Composicion farmaceutica que inhibe o detiene el crecimiento de viruses, en animales, particularmente mamiferos util para tratar infecciones virales |
Country Status (10)
Country | Link |
---|---|
US (1) | US6225307B1 (es) |
EP (1) | EP1169041A2 (es) |
JP (1) | JP2002540149A (es) |
AR (1) | AR018707A1 (es) |
AU (1) | AU764265B2 (es) |
CA (1) | CA2368647A1 (es) |
CO (1) | CO5160289A1 (es) |
NZ (1) | NZ514560A (es) |
PE (1) | PE20001610A1 (es) |
WO (1) | WO2000057868A2 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPR626001A0 (en) * | 2001-07-10 | 2001-08-02 | Mcgregor, Neil | A method of treatment and/or prophylaxis |
AU2003900064A0 (en) * | 2003-01-09 | 2003-01-23 | Penam Investments Pty. Ltd. | A method of treatment or prophylaxis of viral infection. |
JP2005060362A (ja) * | 2003-07-28 | 2005-03-10 | Shionogi & Co Ltd | セスキテルペン誘導体を含有する抗HIV剤、抗BVDV剤、抗HCV剤又は抗CoV剤 |
US20050043253A1 (en) * | 2003-08-19 | 2005-02-24 | Cook Bradley R. | Use of wound healing compositions for prevention of infections and allergies |
CN110818633A (zh) | 2009-01-16 | 2020-02-21 | 埃克塞里艾克西斯公司 | 一种苹果酸盐及其晶型 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2056439B (en) | 1979-07-18 | 1983-03-09 | Wyeth John & Brother Ltd | Hexahydroazepine derivatives |
EP0084920B1 (en) * | 1979-12-05 | 1989-04-19 | Per Arvid Emil Carlsson | New compounds useful as intermediates or starting materials for preparation of therapeutically useful phenyl-azacycloalkanes |
SE8305362D0 (sv) * | 1983-09-30 | 1983-09-30 | Astra Laekemedel Ab | Novel substituted phenylazacycloalkanes, processes for preparation and pharmaceutical preparations for such compounds |
US4724232A (en) * | 1985-03-16 | 1988-02-09 | Burroughs Wellcome Co. | Treatment of human viral infections |
US5114951A (en) | 1989-04-11 | 1992-05-19 | Burroughs Wellcome Company | Agents for combating multiple drug resistance |
FR2729951B1 (fr) * | 1995-01-30 | 1997-04-18 | Sanofi Sa | Nouveaux composes heterocycliques, procede pour leur preparation et compositions pharmaceutiques en contenant |
SK138397A3 (en) * | 1995-04-12 | 1998-05-06 | Procter & Gamble | A pharmaceutical composition containing n-chlorophenylcarbamates and n-chlorophenylthiocarbamates for inhibiting the growth of viruses and cancer |
WO1998045271A1 (en) | 1997-04-10 | 1998-10-15 | F. Hoffman-La Roche Ag | Process for making a butylthio-isoquinoline and intermediates therefor |
-
2000
- 2000-03-29 EP EP00919865A patent/EP1169041A2/en not_active Withdrawn
- 2000-03-29 NZ NZ514560A patent/NZ514560A/xx unknown
- 2000-03-29 WO PCT/US2000/008416 patent/WO2000057868A2/en not_active Application Discontinuation
- 2000-03-29 AU AU40486/00A patent/AU764265B2/en not_active Ceased
- 2000-03-29 CA CA002368647A patent/CA2368647A1/en not_active Abandoned
- 2000-03-29 US US09/538,005 patent/US6225307B1/en not_active Expired - Fee Related
- 2000-03-29 JP JP2000607619A patent/JP2002540149A/ja active Pending
- 2000-03-31 PE PE2000000284A patent/PE20001610A1/es not_active Application Discontinuation
- 2000-03-31 AR ARP000101502A patent/AR018707A1/es not_active Application Discontinuation
- 2000-03-31 CO CO00023485A patent/CO5160289A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU764265B2 (en) | 2003-08-14 |
AU4048600A (en) | 2000-10-16 |
PE20001610A1 (es) | 2001-02-09 |
WO2000057868A3 (en) | 2001-01-11 |
EP1169041A2 (en) | 2002-01-09 |
NZ514560A (en) | 2004-02-27 |
AR018707A1 (es) | 2001-11-28 |
WO2000057868A2 (en) | 2000-10-05 |
CA2368647A1 (en) | 2000-10-05 |
JP2002540149A (ja) | 2002-11-26 |
US6225307B1 (en) | 2001-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE13196A1 (es) | Composiciones topicas acuosas | |
DE60306781D1 (de) | Naturstoffe und deren derivate zur prävention und behandlung von herzkreislauf-, leber- und nierenerkrankungen und für kosmetische anwendungen | |
TNSN07148A1 (en) | (biphenyl) carboxylic acids and derivatives thereof | |
UY26093A1 (es) | Inhibidores de ap2 de bifenilos que contienen compuestos heterociclicos y metodo | |
BR9911043A (pt) | Composição para o tratamento do hiv e outras infecções viróticas | |
BR9714634A (pt) | Carbamatos de benzimidazola-2 para o tratamento de infecções viróticas de câncer | |
ATE260255T1 (de) | 5-oxo-pyrrolidine-2-carbonsäure- hydroxamidderivate | |
FI66722C (fi) | Medel med germicid verkan foer vattensystem | |
BR0314699A (pt) | Composto, composição e métodos para o tratamento da dor e para inibição da função vr1 em uma célula | |
KR910000631A (ko) | 디-3급-부틸(히드록시)페닐 티오 치환된 히드록삼산 유도체 | |
BR0316877A (pt) | Derivados de aril-quinazolina/aril-2-amino-fenil metanona que promovem a liberação de hormÈnio da paratireóide | |
CO5231152A1 (es) | Formulaciones plaguicidas que contienen tensoactivos de piliarilfenolfosfatoester alcoxilado y tensoactivo de lignosulfonato alcoxilado | |
KR950002588A (ko) | 과산화수소 조성물 | |
CO5160289A1 (es) | Composicion farmaceutica que inhibe o detiene el crecimiento de viruses, en animales, particularmente mamiferos util para tratar infecciones virales | |
DE50210655D1 (de) | Stabilisierung kosmetischer oder dermatologischer zubereitungen, welche repellent-wirkstoffe enthalten | |
ES2176719T3 (es) | Derivados de benzopirano que tienen una accion antagonista de leucotrienos. | |
CA2412932A1 (en) | Pleuromutilin derivatives having antibacterial activity | |
BRPI0405080A (pt) | Método para purificação de ácido (met) acrìlico, produto de ácido (met) acrìlico, e, composição de polìmero | |
BR9611700A (pt) | Uso de (tio)ésteres 1,2,3-tiadazolcaboxílicos para o controle de pragas | |
PE103799A1 (es) | Procedimiento de purificacion de mesilato de alatrofloxacino | |
DE602007002794D1 (de) | Behandlung von wässrigen flüssigkeiten und herstellung von anthranilsäure | |
CO5040149A1 (es) | Un mercaptano latente como estabilizador de calor | |
CO5140099A1 (es) | Ciertas caprolactamas sustituidas, composiciones farmaceuticas que las contienen, y su uso en el tratamiento de tumores | |
ES2111938T3 (es) | Composiciones para desodorizar heces animales y el correspondiente proceso desodorizante. | |
ATE332697T1 (de) | Cyanidinmischung zur behandlung von dickdarmkrebs |